Cargando…

The SARS-CoV-2–neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine

Detalles Bibliográficos
Autores principales:	Pedersen, Rune M., Bang, Line L., Tornby, Ditte S., Kierkegaard, Helene, Nilsson, Anna C., Johansen, Isik S., Bistrup, Claus, Jensen, Thøger G., Justesen, Ulrik S., Andersen, Thomas E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society of Nephrology. Published by Elsevier Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450277/ https://www.ncbi.nlm.nih.gov/pubmed/34547366 http://dx.doi.org/10.1016/j.kint.2021.09.006

Ejemplares similares

Neutralization of SARS-CoV-2 Omicron and Delta Variants in Relation to Vaccine-Induced Antibody Levels in Kidney Transplant Recipients and Healthy Controls
por: Pedersen, Rune M., et al.
Publicado: (2022)

Negative SARS-CoV-2 antibodies, T-cell response and virus neutralization following full vaccination in a renal transplant recipient: a call for vigilance
por: Pedersen, Rune M., et al.
Publicado: (2021)

Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients
por: Pedersen, Rune M., et al.
Publicado: (2022)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2022)

Serum Neutralization of Omicron XBB.1.5 in Kidney Transplant Recipients After Bivalent mRNA Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Rectally shed SARS-CoV-2 lacks infectivity: time to rethink faecal–oral transmission?
por: Pedersen, Rune M., et al.
Publicado: (2021)

Rectally shed SARS-CoV-2 in COVID-19 inpatients is consistently lower than respiratory shedding and lacks infectivity
por: Pedersen, Rune Micha, et al.
Publicado: (2022)

Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
por: Holden, Inge K., et al.
Publicado: (2021)

Humoral immune response following a third SARS-CoV-2 mRNA vaccine dose in solid organ transplant recipients compared with matched controls
por: Balsby, Daniel, et al.
Publicado: (2022)

Determinants of Antibody Response to a Third SARS-CoV-2 mRNA Vaccine Dose in Solid Organ Transplant Recipients: Results from the Prospective Cohort Study COVAC-Tx
por: Balsby, Daniel, et al.
Publicado: (2022)

Comparison of six commercially available SARS-CoV-2 antibody assays—Choice of assay depends on intended use
por: Nilsson, Anna Christine, et al.
Publicado: (2021)

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Viral dynamics of SARS-CoV-2 in immunocompromised patients
por: Utzon, Andrea N., et al.
Publicado: (2023)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients
por: Valleriani, Fabrizia, et al.
Publicado: (2021)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Saraceni, Francesco, et al.
Publicado: (2021)

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, following Vaccination with BNT162b2
por: Fylaktou, Asimina, et al.
Publicado: (2023)

Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up!
por: Midtvedt, Karsten, et al.
Publicado: (2021)

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
por: Amit, Sharon, et al.
Publicado: (2021)

Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients
por: Guarino, M., et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine
por: García-Grimshaw, Miguel, et al.
Publicado: (2021)

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Canti, Lorenzo, et al.
Publicado: (2021)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients
por: De Cagna, Maria Rosaria, et al.
Publicado: (2023)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

OC.15.2 HUMORAL RESPONSE TO 2-DOSE BNT162B2 MRNA VACCINE FOR COVID-19 IN LIVER TRANSPLANT RECIPIENTS
por: Guarino, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n558lmkldkc9fbndn8k2h5s5es